High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

Wenrong HuangDepartment of Hematology, Chinese PLA General Hospital, Beijing, China

Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Beijing, China

Honghua LiDepartment of Hematology, Chinese PLA General Hospital, Beijing, China

Wenying KangDepartment of Hematology, Peking Union Medical College Hospital, Beijing, China

Jian BoDepartment of Hematology, Chinese PLA General Hospital, Beijing, China

Yu ZhaoDepartment of Hematology, Chinese PLA General Hospital, Beijing, China

Chunji GaoDepartment of Hematology, Chinese PLA General Hospital, Beijing, China

Daobin ZhouDepartment of Hematology, Peking Union Medical College Hospital, Beijing, China

Li YuDepartment of Hematology, Chinese PLA General Hospital, Beijing, ChinaCorrespondence[email protected]

show all

Click to increase image sizeClick to decrease image size

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

Information for

Open access

Opportunities

Help and information

High-dose melphalan with bortezomib as conditioning regimen for autologous stem cell transplant in patients with newly diagnosed multiple myeloma who exhibited at least very good partial response to bortezomib-based induction therapy

Potential conflict of interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature